argenx SE (ARGX) Could Help Your Portfolio. The Stock Formed Bullish Wedge Up

June 14, 2018 - By Adrian Mccoy

The stock of argenx SE (ARGX) formed an up wedge with $99.20 target or 4.00 % above today’s $95.38 share price. The 7 months wedge indicates low risk for the $3.09 billion company. If the $99.20 price target is reached, the company will be worth $123.68 million more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock decreased 2.97% or $2.92 during the last trading session, reaching $95.38. About 177,397 shares traded or 54.35% up from the average. argenx SE (NASDAQ:ARGX) has risen 340.78% since June 14, 2017 and is uptrending. It has outperformed by 328.21% the S&P500.

More notable recent argenx SE (NASDAQ:ARGX) news were published by: Benzinga.com which released: “23 Stocks Moving In Thursday’s Pre-Market Session” on June 14, 2018, also Seekingalpha.com with their article: “Argenx announces data from phase 1 study of ARGX-113” published on June 14, 2018, Streetinsider.com published: “argenx SE (ARGX) PT Raised to $130 at Piper Jaffray Following Model Adjustments” on June 07, 2018. More interesting news about argenx SE (NASDAQ:ARGX) were released by: Nasdaq.com and their article: “argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating …” published on June 14, 2018 as well as Benzinga.com‘s news article titled: “21 Stocks Moving In Monday’s Pre-Market Session” with publication date: June 11, 2018.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer. The company has market cap of $3.09 billion. The companyÂ’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It currently has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

argenx SE (NASDAQ:ARGX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: